Phaseline

Targets › HSD17B13

HSD17B13 (17-beta-hydroxysteroid dehydrogenase 13): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Metabolic and endocrine, Gastroenterology; next expected readout Jan 2027.

Plays a pivotal role in hepatic lipid metabolism. In vitro, it catalyzes the oxidation of a variety of lipid substrates, including 17beta-estradiol, retinol, retinal, and leukotriene B4..; FUNCTION: [Isoform 2]: Has retinol/retinal dehydrogenase activity in vitro..; FUNCTION: [Isoform 1]: Does not have retinol/retinal dehydrogenase activity in vitro. (UniProt, Q7Z5P4)

Open in Phaseline: the race on HSD17B13, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Visirna Therapeutics HKVSA006
siRNA targeting HSD17β13 mRNA to reduce HSD17β13 protein levels
HSD17B13Phase 2NashJan 2027
Regeneron PharmaceuticalsALN-HSD
HSD17B13 inhibitor via RNA interference (gene silencing)
HSD17B13Phase 2Metabolic Dysfunction-Associated SteatoHepatitis (MASH)Apr 2028

Conditions

Metabolic Dysfunction-Associated SteatoHepatitis (MASH) (1) Nash (1)

Modalities

small molecule (2)

Companies

Regeneron Pharmaceuticals (1) Visirna Therapeutics HK (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.